Bibliographic Details
| Title: |
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab |
| Authors: |
Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez |
| Source: |
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023) |
| Publisher Information: |
BMJ Publishing Group, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2051-1426 |
| Relation: |
https://doaj.org/toc/2051-1426 |
| DOI: |
10.1136/jitc-2023-SITC2023.0595 |
| Access URL: |
https://doaj.org/article/6b475fde214d41829d313ffd4989b729 |
| Accession Number: |
edsdoj.6b475fde214d41829d313ffd4989b729 |
| Database: |
Directory of Open Access Journals |
